GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (XSWX:SANN) » Definitions » 3-Year Dividend Growth Rate

Santhera Pharmaceuticals Holding AG (XSWX:SANN) 3-Year Dividend Growth Rate : 0.00% (As of Jun. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG 3-Year Dividend Growth Rate?

Santhera Pharmaceuticals Holding AG's Dividends per Share for the six months ended in Jun. 2023 was CHF0.00.

The historical rank and industry rank for Santhera Pharmaceuticals Holding AG's 3-Year Dividend Growth Rate or its related term are showing as below:

XSWX:SANN's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 14.15
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Santhera Pharmaceuticals Holding AG's Dividend Payout Ratio for the six months ended in Jun. 2023 was 0.00. As of today, Santhera Pharmaceuticals Holding AG's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Santhera Pharmaceuticals Holding AG's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santhera Pharmaceuticals Holding AG's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's 3-Year Dividend Growth Rate falls into.



Santhera Pharmaceuticals Holding AG 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Santhera Pharmaceuticals Holding AG  (XSWX:SANN) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Santhera Pharmaceuticals Holding AG's Dividend Payout Ratio for the quarter that ended in Jun. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Jun. 2023 )/ EPS without NRI (Q: Jun. 2023 )
=0/ -2.543
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santhera Pharmaceuticals Holding AG 3-Year Dividend Growth Rate Related Terms>


Santhera Pharmaceuticals Holding AG (XSWX:SANN) Business Description

Traded in Other Exchanges
Address
Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.

Santhera Pharmaceuticals Holding AG (XSWX:SANN) Headlines

No Headlines